Michelle Harkins, MD
Pulmonary Disease · Albuquerque, NMNPI 1104832823
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,770 of the $24,440 with a category attached, or 89.1%. 11 manufacturers reported payments, led by GSK at 35.5% of the total. Reporting peaked in 2023 at $10,885 and has fallen 61.4% since, to $4,200 in 2025. Among pulmonary disease clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $788.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- Gilead$7K
- Aquestive Therapeutics, Inc.$4K
- Merck$4K
- Johnson & Johnson$326
- Intuitive Surgical$111
- plus $171 from 5 others
Across 6 payments — averaging $903.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$5K
What the payments were for
- Consulting fees$21,77089%
- Travel & lodging$1,6517%
- Food & beverage$9864%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $8,685 |
| Gilead | 12 | $6,916 |
| Aquestive Therapeutics, Inc. | 1 | $4,200 |
| Merck | 1 | $4,032 |
| Johnson & Johnson | 4 | $326 |
| Intuitive Surgical | 1 | $111 |
| AstraZeneca | 1 | $87 |
| Convatec Inc. | 1 | $31 |
| Bayer | 1 | $24 |
| Abiomed | 1 | $24 |
| Chiesi USA, Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$6,659
- LIBERVANT$4,200
- MONARCH$123
- Da Vinci Surgical System$111
How this compares
$24,440 in reported general payments places this provider in the 95th percentile of 56 pulmonary disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 36 | $138,945 |
| NucalaMepolizumab | 14 | $51,744 |
| TezspireTezepelumab-Ekko | 12 | $50,188 |
| Spiriva RespimatTiotropium Bromide | 38 | $21,409 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $15,962 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $13,442 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $13,163 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $11,331 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $8,473 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,421 |
| Ventolin HfaAlbuterol Sulfate | 40 | $5,679 |
| DuleraMometasone/Formoterol | 13 | $4,510 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $2,942 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,144 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Breo Ellipta, Incruse Ellipta | $8,685 | $78,34980 claims |
| AstraZenecaTezspire, Symbicort | $87 | $66,15071 claims |
| MerckDulera | $4,032 | $4,51013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 pulmonary disease providers in New Mexico.
Other pulmonary disease in Albuquerque
- Lana Melendres GrovesAlbuquerque$1.1M
- Viral GandhiAlbuquerque$14K
- Arjan FloraAlbuquerque$10K
- Akshay SoodAlbuquerque$9K
- Sivakumar NagarajuAlbuquerque$5K
- Ronald BronitskyAlbuquerque$4K
- Daniel NazonAlbuquerque$2K
- Sarah MedrekAlbuquerque$2K
- James BradleyAlbuquerque$1K
- Anne BostwickAlbuquerque$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.